Synchronous bone-metastatic prostate cancer incidence 6% with median survival of 43 months in Chinese cohort

A retrospective cohort study analyzed patients diagnosed with synchronous bone-metastatic hormone-sensitive prostate cancer (SBM-HSPC) at a major tertiary center in China between 2017 and 2023. The study aimed to describe the incidence, patient characteristics, and prognostic factors for overall survival in this population. The sample size and median follow-up duration were not reported.

The analysis found the incidence of SBM-HSPC among prostate cancer patients was 6.09%. The cohort was characterized by high-risk features: 93.1% had a Gleason score of 8 or higher, and 83.7% were classified as having high-volume disease (HVD). The median overall survival for the cohort was 43 months. In a multivariate analysis, HVD was an independent risk factor for worse survival, with a hazard ratio of 2.37 (P = 0.012). Conversely, being aged 60-74 years was associated with better survival compared to other age groups, with a hazard ratio of 0.52 (P = 0.040).

Safety and tolerability data for treatments, including novel hormonal therapies, were not reported. Key limitations include the retrospective, single-center design from China, which limits generalizability to other healthcare settings and populations. The cohort represents a particularly high-risk group, which may not reflect the broader SBM-HSPC population. The study used landmark analysis to mitigate immortal time bias, but the findings remain observational associations, not proof of causation. The practice relevance is restrained; the data provide a prognostic snapshot for a specific high-risk subgroup in a Chinese setting but do not guide specific therapeutic interventions.